Shan Hongli, Li Ke, Zhao Duoyi, Chi Changliang, Tan Qinyuan, Wang Xiaoqing, Yu Jinhai, Piao Meihua
Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.
Department of Orthopedics, the Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Front Pharmacol. 2020 May 19;11:573. doi: 10.3389/fphar.2020.00573. eCollection 2020.
Osteosarcoma (OS) is a serious primary bone malignant tumor that can easily affect children and adolescents. Chemotherapy is one of the important and feasible clinical treatment strategies for the treatment of OS at present, which is severely limited due to insufficient retention time, poor penetration ability, and serious side effects of current anti-tumor drug preparations. In this work, a novel injectable thermo-sensitive hydrogel (mPEG-PLV) loaded with methotrexate and alendronate, and the sustained release at the tumor site synergistically inhibited the progression of OS. The mPEG-PLV shows excellent physical and chemical properties. Compared with other treatment groups, the treatment of gel+ methotrexate + alendronate effectively inhibited the growth of tumor. More importantly, it significantly reduced bone destruction and lung metastasis caused by OS. Therefore, this injectable thermo-sensitive hydrogel drug delivery system has broad prospects for OS chemotherapy.
骨肉瘤(OS)是一种严重的原发性骨恶性肿瘤,容易影响儿童和青少年。化疗是目前治疗骨肉瘤重要且可行的临床治疗策略之一,但由于目前抗肿瘤药物制剂的保留时间不足、渗透能力差和严重的副作用,其受到严重限制。在这项工作中,一种负载甲氨蝶呤和阿仑膦酸盐的新型可注射热敏水凝胶(mPEG-PLV),其在肿瘤部位的持续释放协同抑制了骨肉瘤的进展。mPEG-PLV具有优异的物理和化学性质。与其他治疗组相比,凝胶+甲氨蝶呤+阿仑膦酸盐治疗有效抑制了肿瘤生长。更重要的是,它显著减少了骨肉瘤引起的骨破坏和肺转移。因此,这种可注射热敏水凝胶药物递送系统在骨肉瘤化疗方面具有广阔前景。